Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human NTRK3 Antibodies:
anti-Rat (Rattus) NTRK3 Antibodies:
anti-Mouse (Murine) NTRK3 Antibodies:
Go to our pre-filtered search.
Human Polyclonal NTRK3 Primary Antibody for BR, CyTOF - ABIN5013014
Huang, Lai, Wu, Hsu, Cheng, Lan, Chiu: BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells. in International journal of oncology 2010
Show all 3 Pubmed References
Human Monoclonal NTRK3 Primary Antibody for CyTOF, FACS - ABIN4900210
Delcroix, Curtis, Schiller, Montero-Menei: EGF and bFGF pre-treatment enhances neural specification and the response to neuronal commitment of MIAMI cells. in Differentiation; research in biological diversity 2010
Human Polyclonal NTRK3 Primary Antibody for FACS - ABIN4897363
Rezaee, Rellick, Piedimonte, Akers, OLeary, Martin, Craig, Gibson: Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway. in PLoS ONE 2010
Human Polyclonal NTRK3 Primary Antibody for IP, ELISA - ABIN539562
Menn, Timsit, Calothy, Lamballe: Differential expression of TrkC catalytic and noncatalytic isoforms suggests that they act independently or in association. in The Journal of comparative neurology 1999
Show all 3 Pubmed References
Human Monoclonal NTRK3 Primary Antibody for ELISA, WB - ABIN969324
Hisaoka, Sheng, Tanaka, Hashimoto: Gene expression of TrkC (NTRK3) in human soft tissue tumours. in The Journal of pathology 2002
The authors found a significant association between the localization of RET mutations and the expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid cancer) in patients with medullary thyroid cancer.
High TrkC mRNA expression appears to be frequent in the sonic hedgehog subgroup and seems not to have a major effect on therapy responsiveness in medulloblastoma patients.
Data show that neurotrophin 3 receptor TrkC acts as an activator in tumorigenicity and metastasis of colorectal cancer, and was frequently overexpressed in colorectal cancer (CRC) cells, patients' tumor samples.
LINC00052 could regulate NTRK3 expression by forming complementary base pairing with miR-128 and miR-485-3p to reduce the luciferase activity of NTRK3 3'UTR.
Case Reports: mammary analog secretory carcinoma of the thyroid gland with ETV6 rearrangement and ETV6-NTRK3 gene fusion.
The prevalence of ETV6-NTRK3 kinase fusions were determined in papillary thyroid cancer of adult population
We report the case of a patient with an initial diagnosis of salivary acinic cell carcinoma later reclassified as Mammary analogue secretory carcinoma after next-generation sequencing revealed an ETV6-NTRK3 fusion.
Data suggest that kinase domains of neurotrophin receptor isoforms, TRKA, TRKB, and TRKC, exhibit a bulky phenylalanine gatekeeper, leading to a small and unattractive back pocket/binding site for antineoplastic kinase inhibitors. [REVIEW]
Pan-Trk immunohistochemistry is a time-efficient and tissue-efficient screen for NTRK fusions, particularly in driver-negative advanced malignancies and potential cases of secretory carcinoma and congenital fibrosarcoma.
5 gastrointestinal stromal tumors cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions, are reported.
NTRK fusions occur in a subset of young patients with mesenchymal or sarcoma-like tumors at a low frequency
High expression of TrkC is associated with glioblastoma.
Study found that copy number variations of NTRK3 were associated with platinum-sensitive and platinum-resistant recurrences. Amplification of NTRK3 perfectly predicted platinum-sensitive relapse of ovarian cancer.
we demonstrate the expression of the ETV6-NTRK3 fusion oncogene in a small subset of inflammatory myofibroblastic tumors
ETV6-NTRK3 translocated papillary thyroid carcinomas are locoregionally aggressive and can metastasize distantly.
We report 6 cases of secretory carcinomas of the skin harboring the ETV6-NTRK3 gene fusion
ETV6-NTRK3, MYO5A-NTRK3 and MYH9-NTRK3 fusions are identified in Spitz tumours and demonstrated that NTRK3 fusions constitutively activate the mitogen-activated protein kinase, phosphoinositide 3-kinase and phospholipase Cgamma1 pathways in melanocytes.
A subset of ALK-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism.
TrkC-miR2 as a novel regulator of Wnt signaling, which might be a candidate oncogenic colorectal cancer biomarker.
High expression of TrkA, TrkB, or TrkC was significantly associated with histopathology
This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Signalling through this kinase leads to cell differentiation and may play a role in the development of proprioceptive neurons that sense body position. Mutations in this gene have been associated with medulloblastomas, secretory breast carcinomas and other cancers. Several transcript variants encoding different isoforms have been found for this gene.
ETS related protein-neurotrophic receptor tyrosine kinase fusion protein
, ETV6-NTRK3 fusion
, NT-3 growth factor receptor
, tyrosine kinase receptor C
, neural receptor protein-tyrosine kinase (trkC)
, trkC tyrosine kinase
, neurotrophic tyrosine kinase receptor type 3
, tyrosine kinase C receptor, TrkC receptor, high-affinity neurotrophin receptor
, neurotrophic tyrosine kinase, receptor, type 3
, NT-3 growth factor receptor-like